Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Everest Medicines, Innoviva - LARVOL DELTA

Fulminant Clostridioides Difficile Colitis in Cirrhosis Complicated by Clostridium Perfringens Bacteremia: A Surgical vs Medical Management Dilemma (ACG 2026) - "She was treated for a presumed UC flare with intravenous methylprednisolone. Stool PCR was positive for C. difficile , and oral vancomycin was initiated...Intravenous eravacycline was started due to metronidazole allergy...While early colectomy before septic shock is recommended for source control, operative mortality is extremely high in patients with MELD scores above 30. In this case, surgery was deferred due to prohibitive risk; however, progression to perforation and overwhelming sepsis raises the question of whether earlier surgical intervention might have altered the outcome despite severe cirrhosis."

Acute Kidney Injury • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Renal Disease • Septic Shock • Ulcerative Colitis

In Vitro Activity of Omadacycline and Eravacycline against Nocardia brasiliensis Isolates (EADV 2026) - No abstract available

Preclinical • Infectious Disease

Evaluation of empiric intraoperative antibiotic regimens for coverage of donor-derived infection in lung transplantation: A single-center retrospective study (TTS 2026) - "The current empiric triple regimen of "vancomycin + imipenem + caspofungin" (used in 91.5% of cases) demonstrated an overall theoretical coverage rate of only 28.6% against DDI pathogens, with coverage rates of 20.0% against A. baumannii and 16.3% against carbapenem-resistant organisms...Commonly used adjusted antibiotics included polymyxin E (55.0%), eravacycline (45.0%), and ceftazidime-avibactam (37.5%).The composition of DDI pathogensthe theoretical coverage of existing antibiotic regimens against DDI pathogens The incidence of strictly defined DDI after lung transplantation at our center is 21.6%. The incidence of strictly defined DDI after lung transplantation at our center is 21.6%. Current empiric intraoperative antibiotic regimens provide limited coverage, particularly against multidrug-resistant organisms. An individualized, targeted intraoperative antibiotic prophylaxis strategy based on donor pathogen screening is urgently warranted."

Retrospective data • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Transplantation

Comparative Effectiveness and Safety of Eravacycline- versus Tigecycline-Based Therapy in Critically Ill Patients with Carbapenem-Resistant Acinetobacter baumannii Infection: A Multicenter Retrospective Cohort Study (IDWeek 2026) - No abstract available

HEOR • Retrospective data • Infectious Disease

Retrospective Comparison Review of Carbapenem-Resistant Acinetobacter baumanii Management with Eravacycline or Cefiderocol in Northeast Acute Care Hospital with Attached LTACH (IDWeek 2026) - No abstract available

Retrospective data • Review • Infectious Disease

Eravacycline for multidrug resistance bacteria-associated HAP/VAP: a real-world study of clinical efficacy and lung penetration (ERS 2026) - "These real-world data support its use as part of combination regimens for severe drug-resistant pneumonia in the ICU."

Clinical • Real-world • Real-world evidence • Infectious Disease • Pneumonia • Respiratory Diseases

Real-World Therapy with Eravacycline for Complex Infections Caused by Carbapenem-Resistant Pathogens with a Focus on Patients with Severe Burns. (PubMed, Infect Dis Ther) - "In this small retrospective study presenting preliminary real-world observational data, ERV proved to be a safe and promising treatment option for complex infections caused by carbapenemase-producing Klebsiella pneumoniae and Acinetobacter baumannii strains, characterized by few side effects and good efficacy even outside indications specified in the approval studies."

Journal • Real-world evidence • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Multiple Myeloma • Oncology • Pneumonia • Respiratory Diseases • Thermal Injury

In vitro activity of beta-lactam/beta-lactamase inhibitors, colistin, tigecycline, and eravacycline against carbapenemase-producing uropathogenic Enterobacterales. (PubMed, Future Microbiol) - "In contrast, blaKPC and blaOXA-48 encoding isolates remained susceptible against CZA and IMR while colistin, tigecycline, and eravacycline retained their activities. It highlighted the importance of molecular surveillance to guide appropriate therapy for CPE-associated UTIs."

Journal • Preclinical • Infectious Disease • Nephrology

Case Report: Diagnosis and management of severe pneumonia caused by complex mixed infection with multidrug-resistant bacteria and fungi after liver retransplantation. (PubMed, Front Surg) - "Targeted anti-infective therapy was initiated promptly, including aztreonam/avibactam, polymyxins, eravacycline, isavuconazole, and caspofungin during the treatment course. For complex mixed infections following liver retransplantation, continuous evaluation of pathogen profiles, immune status, and organ function is critical for guiding individualized treatment strategies. This case highlights that, while potent targeted anti-infective therapy may be life-saving, close monitoring and prompt intervention for treatment-related adverse events and complications are equally essential to achieve a balance between therapeutic benefit and clinical risk under critical conditions."

Journal • Gastroenterology • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

TAILOR: Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation (clinicaltrials.gov) - P3 | N=168 | Not yet recruiting | Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

New P3 trial • Transplantation

Real-world safety profile of eravacycline compared with tigecycline, minocycline, and meropenem: a comparative pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Off-label use, particularly for pulmonary Mycobacterium abscessus infection, predominates in real-world practice. These findings are hypothesis-generating and require validation in prospective, controlled studies."

Adverse events • Journal • Real-world evidence • Infectious Disease • Metabolic Disorders • Pancreatitis • Pneumonia • Respiratory Diseases

Development and validation of a UHPLC-MS/MS method for the quantification of Eravacycline in human serum and its application to therapeutic drug monitoring. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - No abstract available

Journal

Intrapulmonary pharmacokinetics and safety of eravacycline in critically ill patients with HAP/VAP caused by carbapenem-resistant Acinetobacter baumannii and Enterobacterales: a prospective study. (PubMed, Int J Antimicrob Agents) - "Eravacycline achieved substantial pulmonary exposure in critically ill patients with HAP/VAP despite reduced plasma exposure, with acceptable safety and encouraging clinical responses. Notably, eravacycline's independent contribution to clinical outcomes cannot be determined due to concurrent antimicrobial use."

Journal • PK/PD data • Infectious Disease • Pneumonia • Respiratory Diseases

In Vitro Antibacterial Activity of Sulbactam-Durlobactam and Eravacycline Against Carbapenem-Resistant Acinetobacter baumannii in China and Analysis of Sulbactam-Durlobactam Resistance Mechanisms. (PubMed, Pol J Microbiol) - "Despite the extensive-drug-resistant (XDR) nature of current CRAB isolates, they maintain high sensitivity to SUL-DUR and ERV. Our findings underscore that SUL-DUR and ERV represent highly promising therapeutic options with significant development potential and broad clinical application prospects for the management of CRAB-related infections."

Journal • Preclinical • Infectious Disease

Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review. (PubMed, J Clin Med) - "Eravacycline (EVT), formerly known as TP-434, is a newly developed non-beta-lactam, fully synthetic tetracycline derivative, approved for the treatment of complicated intra-abdominal infections (cIAIs) in adults. The analysis demonstrated significant efficacy of EVT across a wide range of in vitro and in vivo studies against MDR GNB, including carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE) and Gram-positive vancomycine-resistant pathogens. The broad spectrum of activity and favorable safety profile of EVT are well-documented in the treatment of critically ill patients. However, its efficacy against clinically relevant Gram-negative bacteria varies depending on specific species and resistance phenotypes, particularly among carbapenem-resistant and extensively drug-resistant (XDR) isolates."

Journal • Review • Infectious Disease

Eravacycline in Critically Ill Patients with Multidrug-Resistant Gram-Negative Infections: A Real-World Cohort Study. (PubMed, J Clin Med) - "The dissociation between microbiological eradication and survival suggests that outcomes are more closely related to host factors and unresolved systemic inflammation than to pathogen clearance alone. Eravacycline remains one of the few agents active against MDR Gram-negative pathogens (with no activity against Pseudomonas aeruginosa), frequently used off-label; larger controlled studies are needed to establish efficacy beyond complicated intra-abdominal infections."

Journal • Real-world evidence • Critical care • Infectious Disease • Inflammation • Pneumonia

In Vitro Assessment of Eravacycline and Polymyxin B Combination Against Carbapenem-Resistant Klebsiella pneumoniae. (PubMed, J Glob Antimicrob Resist) - "The ERV/PMB combination exhibits potent synergistic and additive antibacterial activity against CRKP, particularly against strains non-susceptible to both agents, and may be especially valuable for infections caused by ST11 KPC-2-producing strains."

Journal • Preclinical • Infectious Disease • Pneumonia

Comparative evaluation of disc diffusion, Liofilchem™ MTS strips, Etest® Biomérieux with broth microdilution for eravacylin susceptibility testing. (PubMed, J Antimicrob Chemother) - "While eravacycline shows strong in vitro activity against carbapenem-resistant Enterobacterales, current gradient strip and disc diffusion methods demonstrate limited reliability on Enterobacterales, although good performances were achieved for E. coli. These findings highlight the need for cautious interpretation and further optimization of routine susceptibility testing methods."

Clinical • Journal • Infectious Disease

A Real-World, Multicenter, Prospective, Historically Controlled, Cohort Observational Study to Evaluate the Efficacy and Safety of Eravacycline-Based Combination Antibiotic Regimens in Acute Leukemia Patients with Chemotherapy-Induced Febrile Neutropenia (ChiCTR) - P=N/A | N=315 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of the Army Medical University; The Second Affiliated Hospital of the Army Medical University

New trial • Real-world evidence • Chemotherapy-Induced Neutropenia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology

Investigating the anticancer activity of eravacycline in pancreatic cancer via target-based deep learning and experimental validation. (PubMed, Brief Bioinform) - "Our findings demonstrate an association between Erav treatment and reduced POLK protein expression in the studied mutant p53 PDAC model, supporting POLK as a prioritized candidate for further investigation and providing preliminary mechanistic insight into Erav activity. This integrative computational-experimental pipeline offers a robust strategy for accelerating drug repurposing in oncology."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • POLK • TP53

Effectiveness and safety of eravacycline-based regimens for resistant acinetobacter baumannii infections: a systematic review and meta-analysis. (PubMed, Expert Rev Anti Infect Ther) - "Complementary single-arm pooled estimates among eravacycline-treated cohorts were favorable. This meta-analysis strengthens the evidence base for eravacycline effectiveness in resistant A. baumannii infections and supports its consideration when preferred regimens are not feasible; adequately powered randomized trials are needed to define optimal positioning."

Journal • Retrospective data • Review • Infectious Disease • Respiratory Diseases

Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review. (PubMed, Antibiotics (Basel)) - "Given the limited number of antibiotics for treating CDI and fidaxomicin nonavailability in many countries, it is necessary to conduct more extensive laboratory and clinical studies of promising antibiotics such as ibezapolstat, delafloxacin, lascufloxacin, omadacycline, eravacycline, ridinilazole, and CRS3123...Research on rifasutenizol for bacterial vaginosis, sarecycline and nadifloxacin for acne vulgaris and amixicile for periodontal diseases needs to be expanded. For H. pylori infection, delafloxacin, sitafloxacin, nemonoxacin, zoliflodacin, and rifasutenizol may improve the suboptimal success of most eradication regimens...Establishing more research groups, careful examination of market issues, and additional approaches, such as nanomaterials, efflux pump inhibitors, phage therapy, and CRISPR-Cas systems, should be beneficial. Notwithstanding the difficulties, there are many opportunities to promote research on and potential use of newer antibiotics which show..."

Journal • Review • Acne Vulgaris • Dental Disorders • Dermatology • Infectious Disease • Periodontitis • Vaginitis

Prosthetic Valve Endocarditis by Acinetobacter baumannii: Case Report and Systematic Descriptive Review. (PubMed, Pathogens) - "This case, together with previously reported observations, highlights the severity of EI by A. baumannii and the need of multidisciplinary management."

Journal • Review • Cardiovascular • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

The Rise in Carbapenem-Resistant Acinetobacter baumannii and the Emergence of Eravacycline as a Treatment Strategy: A Narrative Review. (PubMed, Pathogens) - "Finally, the article outlines future research directions and treatment strategies. Due to the narrative nature of this review, no systematic methodology (e.g., PRISMA) was applied, and the available clinical evidence, particularly for CRAB infections, remains limited."

Journal • Review • Infectious Disease

Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian analysis based on the FAERS database. (PubMed, Front Antibiot) - "A total of 346 coagulation dysfunction reports with the novel tetracycline-class drugs as suspected drugs were screened, including 327 for tigecycline, 6 for omadacycline, and 13 for eravacycline. Distinctive reporting patterns of coagulation abnormalities were observed across the three novel tetracyclines, with visible discrepancies in patient age, gender, therapeutic indications, daily dosage, clinical outcomes, and adverse event onset time. Based on the above findings, clinicians should maintain high vigilance against the potential coagulation abnormalities induced by novel tetracyclines, and implement standardized and rational therapeutic drug monitoring during clinical medication practice."

Journal • Hematological Disorders